FDA Approves AllerClear OTC: What You Need to Know

Key Takeaways

• Main news: The U.S. Food and Drug Administration (FDA) has granted FDA Allergo's AllerClear approval for over-the-counter (OTC) use, allowing it to be sold without a prescription for the treatment of seasonal allergic rhinitis.
• Clinical impact: AllerClear contains a second-generation antihistamine that is designed to minimize sedation, offering relief from common allergy symptoms.
• Market implications: This OTC approval provides Allergo with a new competitive advantage in the crowded allergy medication market, increasing accessibility for consumers.
• Next steps: Allergo will now focus on manufacturing, distribution, and marketing to make AllerClear widely available to consumers for the upcoming allergy season.

The FDA Allergo's AllerClear approval marks a significant step in expanding access to allergy relief, with the FDA granting over-the-counter (OTC) status to Allergo's AllerClear for treating seasonal allergic rhinitis. This decision allows consumers to purchase AllerClear without a prescription, addressing symptoms such as sneezing, runny nose, and itchy eyes. Why it matters: This approval increases patient access to effective allergy treatment without a prescription, addressing a large patient population with seasonal allergic rhinitis.

Drug Overview

AllerClear is a second-generation antihistamine. Its mechanism of action involves selectively blocking H1 histamine receptors, which reduces allergic symptoms by preventing histamine-mediated responses. It is indicated for the treatment of seasonal Allergic Rhinitis, alleviating symptoms such as sneezing, runny nose, and itchy eyes.

Clinical Insights

Clinical trials supporting the OTC approval of AllerClear included well-controlled studies assessing symptom relief and safety profiles in adult and adolescent populations. The primary endpoint in these trials was the reduction in nasal and ocular symptom scores and patient-reported outcomes. Class-typical adverse events include mild sedation, headache, dry mouth, and gastrointestinal discomfort. Second-generation antihistamines generally have a favorable safety profile with minimal central nervous system effects.

Regulatory Context

The FDA's Center for Drug Evaluation and Research (CDER) evaluated AllerClear’s switch from prescription to OTC status. This approval process involved a New Drug Application (NDA) and required the demonstration of labeling comprehension and self-selection studies to ensure safe consumer use. This OTC approval reflects the FDA’s broader initiative to expand access to effective allergy treatments.

Market Impact

The US OTC allergy medication market is highly competitive, dominated by brands like loratadine (Claritin), cetirizine (Zyrtec), and fexofenadine (Allegra). AllerClear’s OTC approval positions Allergo to capture market share by providing a new accessible option for seasonal allergy sufferers. Approximately 20% of the US population experiences seasonal Allergic Rhinitis annually, representing a significant patient base. Compared with other OTC antihistamines, AllerClear provides another option for consumers. The OTC switch may pressure pricing and marketing strategies among competitors, potentially benefiting consumers.

Future Outlook

Allergo may explore label expansions to include additional indications or patient populations. What to watch next: Future studies might investigate AllerClear in combination with other allergy medications or formulations.

Frequently Asked Questions

References

References

1. U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-20.

Related coverage

• FDA Approves Lumasiran for PH1: What BD and Investors Should Know
• Exclusive: FDA issues industry-friendly gene therapy guidance: What BD teams need to know
• FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch